Phase I/II clinical trial to evaluate the safety and efficacy of Allogenic Adipose
Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia
NCT04366323Sars-CoV2Drug: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS
Measure: Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate Time: 12 months Measure: Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate Time: 28 days